Last reviewed · How we verify
NCT03072979
A Study to Quantify Tumour Perfusion for Spine Metastasis Treated With Stereotactic Body Radiotherapy (SBRT)
trial testing Stereotactic body radiotherapy in Spine Metastasis in 18 participants. Status unknown.
31 December 2017
Quick facts
| Lead sponsor | National University Hospital, Singapore |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 18 |
| Start date | 21 January 2017 |
| Primary completion | 31 December 2017 |
| Estimated completion | 31 December 2018 |
| Sites | 1 location across Singapore |
Drugs / interventions tested
- Stereotactic body radiotherapy
Conditions studied
- Spine Metastasis — all drugs for Spine Metastasis →
Sponsor
National University Hospital, Singapore
Who can join
21 and older, any sex, with Spine Metastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pre-clinical evidence suggests that radiotherapy reduces tumour-associated vasculature. The investigators will conduct a single-arm prospective study to quantify the reduction in tumour vasculature post-radiotherapy
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Quantifying the changes in the tumour vascular micro-environment in spinal metastases treated with stereotactic body radiotherapy - a single arm prospective study.
Vellayappan B, Cheong D, Singbal S, Tey J, et al · · 2022 · cited 9× · PMID 36503714 · DOI 10.2478/raon-2022-0046
Verify or expand the search:
- PubMed search for NCT03072979
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Stereotactic body radiotherapy
Trials testing the same drug.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT06489821 — STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer · NA · not yet recruiting
- NCT06185556 — COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Per · Phase 2, PHASE3 · recruiting
- NCT06595108 — Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma · NA · recruiting
- NCT06313190 — Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402) · Phase 2 · recruiting
Other recruiting trials for Spine Metastasis
Currently open trials in the same condition.
- NCT03853434 — Efficacy of Angiographic Embolization vs Non-embolization of Moderate/Poor Vascularized Vertebral Metastases on Intraope · NA · recruiting
Other National University Hospital, Singapore trials
Trials by the same sponsor.
- NCT06027983 — Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors · Phase 1, PHASE2 · not yet recruiting
- NCT07460505 — Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure · NA · not yet recruiting
- NCT07319676 — Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas · Phase 1, PHASE2 · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07091175 — Dupilumab Therapy in Nephrotic Syndrome in Children · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03072979 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National University Hospital, Singapore
- Last refreshed: 8 March 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03072979.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing